Ganwei
PreclinicalBiologic
Ganwei is one of 25 biologic programs targeting Non-Alcoholic Fatty Liver Disease. It is currently in Preclinical.
1
Indications
2
Total Trials
1
Active Trials
24
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
30 competitors in Non-Alcoholic Fatty Liver Disease
#DrugCompanyPhaseTrials
1Actos
TakedaApproved
Avandia
Jazz PharmaceuticalsApproved
Bayer Aspirin
BayerApproved
Actigall
AbbVieApproved
Calciferol
Jazz PharmaceuticalsApproved
Uloric
TakedaApproved
Crestor
AstraZenecaApproved
Januvia
ZZydus Therapeutics Inc.
Approved
Jardiance
Boehringer IngelheimApproved
Glucophage
EMD SeronoApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ganwei. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Preclinical[1]
- Company
- TTaipei City Hospital